# A nurse is caring for a patient with stage 4 chronic kidney disease (CKD) who has developed hyperphosphatemia. Which nursing intervention should be the priority?

> source: MyMerci (mymerci.kr)  
> url: https://mymerci.kr/pages/nclex_q.php?qn_id=541385  
> language: ko  
> subject: Adult Health

## 문제

A nurse is caring for a patient with stage 4 chronic kidney disease (CKD) who has developed hyperphosphatemia. Which nursing intervention should be the priority?

## 보기

1. Educate the patient about dietary phosphorus restriction and phosphate binder administration **✔ 정답**
2. Monitor for signs of hypocalcemia and tetany due to elevated phosphorus
3. Increase fluid intake to promote phosphorus excretion through the kidneys
4. Administer calcium supplements to counteract phosphorus elevation in blood

**정답: 1**

## 해설

In stage 4 CKD with hyperphosphatemia, patient education on dietary phosphorus restriction and phosphate binder administration is the priority for long-term management and prevention of complications like bone disease and cardiovascular calcification. Other options address monitoring or acute interventions but do not provide sustainable management.

## 심화 해설

Understanding the Priority in Hyperphosphatemia Management for CKD Stage 4

The correct answer is to educate the patient about dietary phosphorus restriction and phosphate binder administration. In a patient with stage 4 chronic kidney disease (CKD), the kidneys' ability to excrete phosphorus is significantly diminished, leading to hyperphosphatemia. The priority nursing intervention is to address the primary source of phosphorus and its absorption, which directly targets the pathophysiological mechanism of the problem.

Why This Is the Priority Intervention

Hyperphosphatemia in CKD is driven by a positive phosphorus balance, primarily from dietary intake exceeding the reduced renal clearance. The foundational management strategy, as highlighted in the literature, involves a two-pronged approach: limiting phosphorus intake and reducing its gastrointestinal absorption. The phosphate-lowering medications, or binders, work within the gut to prevent absorption, and their effectiveness is contingent on proper administration with meals [1]. Without this foundational knowledge and adherence, other interventions will have limited long-term success. A hierarchical management model, including pharmacist-led education, has been shown to effectively improve phosphorus control, underscoring the critical role of patient education and medication management [3].

Analysis of Incorrect Options

Option 2: Monitor for signs of hypocalcemia and tetany due to elevated phosphorus.

While monitoring for hypocalcemia is an important nursing action because elevated phosphorus binds with calcium, decreasing ionized calcium levels, it is not the priority intervention. Monitoring is a passive assessment, whereas the priority is an active intervention that treats the root cause of the hyperphosphatemia. The direct toxicity of elevated phosphate concentrations has been well-established, making its reduction the primary clinical goal [1].

Option 3: Increase fluid intake to promote phosphorus excretion through the kidneys.

This intervention is ineffective and potentially dangerous for a patient with stage 4 CKD. The damaged kidneys have a severely limited capacity to excrete phosphorus, regardless of fluid intake. Forcing fluids could lead to fluid volume overload, hypertension, and edema without meaningfully lowering serum phosphorus levels. The primary route for phosphorus removal in advanced CKD is through dialysis and gastrointestinal binding, not native kidney excretion [1].

Option 4: Administer calcium supplements to counteract phosphorus elevation in blood.

While calcium-based phosphate binders exist, administering calcium supplements with the sole intent of "counteracting" phosphorus in the blood is a misunderstanding of the therapy. The goal is to bind phosphorus in the gastrointestinal tract, not to create a chemical reaction in the bloodstream. Indiscriminate calcium administration can lead to hypercalcemia and increase the risk of vascular calcification, a serious complication in CKD. The focus must be on binding dietary phosphorus before it is absorbed, which is achieved through proper timing of binder administration with meals [1]. Newer agents, like tenapanor, even work through a non-binder mechanism by reducing paracellular phosphate absorption, further emphasizing that the gut is the therapeutic target .References (research sources)

- [1]Phosphate-latest news and ongoing trials.Research articleParpia AS, Kumra R, Mansell C, Harel Z, Perl J, Ben-Bassat OK, Wald R. (2026) · DOI: 10.1093/ckj/sfag108

- [3]Effectiveness of a hierarchical pharmacist management model on reducing hyperphosphatemia in hemodialysis patients in China: a multicenter randomized study.RCT/clinical trialYe X, Wu S, Gu EM, Jiang X, Liu W, Ding T, Xu D, Pan Z, Tang H, Hu B, Tu Q, Wang L, Huang P. (2026) · DOI: 10.1038/s41598-025-34974-5

## 임상 시나리오

Managing Hyperphosphatemia in CKDPrioritizing Dietary Control and Phosphate Binders
The priority intervention for hyperphosphatemia in stage 4 CKD is patient education on dietary phosphorus restriction and phosphate binder administration. This directly targets the primary source of phosphorus accumulation due to negligible renal excretion.

Phosphate binders must be administered with meals to chelate dietary phosphorus in the gut and prevent absorption. Common binders include calcium acetate and sevelamer. Dietary teaching should focus on avoiding high-phosphorus foods like dairy, nuts, and processed meats.

CautionDo not prioritize increasing fluid intake; damaged kidneys cannot excrete phosphorus effectively. Avoid giving calcium supplements without binder therapy, as this can raise the risk of metastatic calcification when the calcium-phosphorus product is high.

## 핵심 개념

- **Phosphate Binders** — Medications that bind to dietary phosphorus in the gastrointestinal tract, preventing its absorption. They must be taken with meals to be effective.
- **Hyperphosphatemia** — An elevated serum phosphate level, common in CKD due to reduced renal excretion, leading to secondary hyperparathyroidism and bone disease.
- **Chronic Kidney Disease (CKD) Stage 4** — Severe reduction in glomerular filtration rate (GFR 15-29 mL/min), characterized by significant loss of renal excretory and regulatory functions.

## 같은 주제 문제

- [A nurse is assessing a patient with stage 4 chronic kidney disease (CKD). Which assessment…](https://mymerci.kr/pages/nclex_q.php?qn_id=541380)
- [A nurse is assessing a 58-year-old patient with stage 4 chronic kidney disease (CKD). Whic…](https://mymerci.kr/pages/nclex_q.php?qn_id=541381)
- [A nurse is assessing a 58-year-old patient with stage 4 chronic kidney disease (CKD). Whic…](https://mymerci.kr/pages/nclex_q.php?qn_id=541382)
- [A nurse is caring for a client with stage 3 chronic kidney disease (CKD) who has developed…](https://mymerci.kr/pages/nclex_q.php?qn_id=541383)
- [A nurse is caring for a client with end-stage renal disease (ESRD) on hemodialysis who has…](https://mymerci.kr/pages/nclex_q.php?qn_id=541384)
- [A nurse is caring for a client with stage 5 chronic kidney disease (CKD) who has developed…](https://mymerci.kr/pages/nclex_q.php?qn_id=541386)
- [A nurse is caring for a client with stage 3 chronic kidney disease (CKD) who presents with…](https://mymerci.kr/pages/nclex_q.php?qn_id=541387)
- [A nurse is caring for a client with stage 4 chronic kidney disease (CKD) who presents with…](https://mymerci.kr/pages/nclex_q.php?qn_id=541388)

---

More free questions: [기출문제](https://mymerci.kr/)

_학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요._